JOHN DE VERA: Open Payments
NPI 1437891561 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,319 in 40 payments from 13 companies in 2025. Trend: 2023 $591 · 2024 $1,118 · 2025 $1,319
Food & beverage: $1,215Education: $104
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 20 | $604 |
| Lilly USA, LLC | 3 | $190 |
| ABIOMED | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Amgen Inc. | 2 | $63 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
| Neurelis, Inc. | 2 | $45 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Dexcom, Inc. | 1 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
Products named: AUSTEDO XR, UZEDY, ZEPBOUND, REXULTI, MOUNJARO, INGREZZA, VALTOCO, Kerendia.
Industry payments across CA — which companies pay providers there.
